Fortuna Mining Corp. Common Shares vs uniQure N.V. Ordinary Shares — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.42 (market cap $3.01B), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: Fortuna Mining Corp. Common Shares is far larger — about 2.1× uniQure N.V. Ordinary Shares's market cap, and Fortuna Mining Corp. Common Shares is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FSM | QURE | |
|---|---|---|
Market Cap | $3.01B | $1.45B |
Volume | 7,155,106 | 3,323,243 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $70.59 |
52-Week Low | $7.84 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $2.63B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
Fortuna Mining (FSM) trades at $10.58, down 1.67% on the day, amid a bearish technical signal. The company reported strong 2025 results with $947M revenue and $287M net income, but recent quarters have missed EPS expectations. Analyst consensus is bullish with 4 buy ratings, while technical indicators show mixed signals with a bearish moving average trend but neutral oscillators.
FSM presents a value opportunity with low P/E of 8.89 and robust profitability margins, but faces risks from production volatility and execution of growth projects. The stock's near-term performance hinges on Q3 2026 earnings and progress toward its 500,000-ounce gold production target by 2028.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →